Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 276 to 300 of 881

TitleReference numberPublishedLast updated
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)TA859
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinomaTA857
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinomaTA858
Upadacitinib for treating moderately to severely active ulcerative colitisTA856
Avatrombopag for treating primary chronic immune thrombocytopeniaTA853
Cabozantinib for previously treated advanced hepatocellular carcinomaTA849
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapyTA850
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancerTA851
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatmentsTA852
Esketamine nasal spray for treatment-resistant depressionTA854
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)TA848
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)TA845
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)TA846
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)TA847
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)TA843
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)TA844
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA841
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)TA842
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)TA840
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)TA838
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA836
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanomaTA837
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroidsTA832
Zanubrutinib for treating Waldenstrom's macroglobulinaemiaTA833
Fostamatinib for treating refractory chronic immune thrombocytopeniaTA835

Results per page

  1. 10
  2. 25
  3. 50
  4. All